ArticleOncoTargets and therapy2023

Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion.

Jing He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.